Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Prospective European Trial Explores Cancer-Nutrition Links Links

October 1, 2000
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 10
Volume 9
Issue 10

WASHINGTON-Size matters, especially in epidemiologic studies. The European Prospective Investigations into Cancer and Nutrition (EPIC) was founded on that principle in 1992, said Elio Riboli, MD, ScM, MPH.

WASHINGTON—Size matters, especially in epidemiologic studies. The European Prospective Investigations into Cancer and Nutrition (EPIC) was founded on that principle in 1992, said Elio Riboli, MD, ScM, MPH.

Since then, the EPIC researchers have recruited 484,000 subjects from nine European countries for a multicenter, prospective study of the relationship between dietary, genetic, metabolic, and lifestyle characteristics and the risk of cancer and cardiovascular disease.

Dr. Riboli, chief of the Nutrition and Cancer Unit of the International Agency for Research on Cancer, Lyon, France, described the research project at the 10th Annual Research Conference of the American Institute for Cancer Research (AICR).

“We know that a plant-based diet protects against cancers of the colorectum, stomach, upper aerodigestive tract, and possibly others,” Dr. Riboli said. “We also know that salty foods raise the risk of stomach cancer and that there is information suggesting that eating meat increases colorectal cancer risk. But we need to know more: Which foods? Which vegetables? What is their chemical and physical structure?”

In short, while “eat more fruits and vegetables” may be good advice for the public, more detailed information is needed to determine the role of nutrition in initiating or preventing the development of many cancers, he said.

An advantage of studying populations across Europe (in Denmark, France, Germany, Greece, Italy, the Netherlands, Spain, Sweden, and the United Kingdom) is that wide variations in cancer incidence and dietary practices can be explored.

For instance, Dr. Riboli said, the breast cancer rate in Scotland is four times higher than the rate in Sicily or southern Spain, while the stomach cancer rate is highest in central Spain and northern Italy and lowest in England.

The EPIC researchers have collected a detailed questionnaire from each study subject on diet, lifestyle, illness, medication use, physical activity, alcohol and tobacco use, reproductive and contraceptive history, and socioeconomic factors. Anthropometric measurements have also been taken.

The food questionnaire lists 150 to 300 food choices, and a more detailed inquiry into a 1-day “actual” diet taken from 7% of the respondents will cover 3,000 possible food descriptions and 700 recipes tailored for each country. “At worst,” Dr. Riboli quipped, “we can publish books of recipes, if we fail as cancer researchers.”

To date, the EPIC group has taken blood samples from 387,000 subjects. Blood from each subject is parceled out into 28 small (0.5 mL) plastic straws containing plasma, serum, buffy coat or red blood cells, and stored in liquid nitrogen for study over the next 10 to 15 years. The storage system is designed to withstand power outages as long as 4 months without refilling.

EPIC will use these stored biologic samples to measure biomarkers that will then be correlated with the 17,000 cases of cancer expected to occur in this cohort by 2002. Prediagnostic levels of steroid hormones, insulin-like growth factors, and other metabolic factors will be correlated with inherited genetic susceptibilities.

“We are trying to go beyond the black box of epidemiology and identify mechanisms that lead to cancers,” Dr. Riboli said. This may lead to answers to current puzzles such as whether levels of eicosapentaenoic acid (EPA) from fish oil are related to cancer risk. EPA levels have been shown to be higher in Denmark and lower among a group of vegetarians in Oxford, UK.

These biomarker studies may also lead to improved measurements of data collected on dietary questionnaires, whose accuracy has long been debated by nutrition researchers.

Articles in this issue

HER-2/neu Activation May Predict Breast Cancer Prognosis
Company Offers Computer-Aided Detection of Breast Cancer
Adjuvant Tamoxifen Equally Effective in Black and White Breast Cancer Patients
ASBD, an Interdisciplinary Group, Fights Breast Cancer
How Employers Can Help Caregivers in the Workplace
Only Slight Improvement in Hepatocellular Carcinoma Survival
New BRCA1 Mutations Found in Black and Hispanic Women
Study Shows Profile of At-Risk Elderly Lung Cancer Patients
Scientific Studies Support Strategies to Curb Nicotine Addiction
Smoking Declines Among High School Males, But Not Females
Cuts in Medicare Reimbursement for Cancer Drugs on Hold
New Chemoprevention Trials of COX-2 Inhibitors Underway
Panel to Recommend Changes to Cancer Act
NIH Adjuvant Therapy for Breast Cancer Panel to Address 7 Issues
Data Support Chemo for All Young Breast Cancer Patients

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
2 experts are featured in this series.
4 experts in this video
5 experts are featured in this series
Related Content

Leading experts gathered in Orlando, FL, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.

National ICE-T Conference Aims to Make CAR T Safer and More Available

Tim Cortese
August 3rd 2025
Article

Leading experts gathered in Orlando, FL, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.


Navigating Second-Line Treatment Options in Urothelial Carcinoma

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 3rd 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.


Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

CAR T-Cell Therapies Show Superior Efficacy, Safety in Multiple Myeloma

Tim Cortese
August 3rd 2025
Article

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.


Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
August 3rd 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.


An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent.

VT3989 Receives Orphan Drug Designation for the Treatment of Mesothelioma

Roman Fabbricatore
August 3rd 2025
Article

An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent.


Findings from the phase 3 TALAPRO-2 trial showed that the safety profile of talazoparib was consistent with its known profile in metastatic CRPC.

Talazoparib Combo Significantly Improves Overall Survival in Metastatic CRPC

Roman Fabbricatore
August 3rd 2025
Article

Findings from the phase 3 TALAPRO-2 trial showed that the safety profile of talazoparib was consistent with its known profile in metastatic CRPC.

Related Content

Leading experts gathered in Orlando, FL, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.

National ICE-T Conference Aims to Make CAR T Safer and More Available

Tim Cortese
August 3rd 2025
Article

Leading experts gathered in Orlando, FL, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.


Navigating Second-Line Treatment Options in Urothelial Carcinoma

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 3rd 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.


Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

CAR T-Cell Therapies Show Superior Efficacy, Safety in Multiple Myeloma

Tim Cortese
August 3rd 2025
Article

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.


Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
August 3rd 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.


An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent.

VT3989 Receives Orphan Drug Designation for the Treatment of Mesothelioma

Roman Fabbricatore
August 3rd 2025
Article

An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent.


Findings from the phase 3 TALAPRO-2 trial showed that the safety profile of talazoparib was consistent with its known profile in metastatic CRPC.

Talazoparib Combo Significantly Improves Overall Survival in Metastatic CRPC

Roman Fabbricatore
August 3rd 2025
Article

Findings from the phase 3 TALAPRO-2 trial showed that the safety profile of talazoparib was consistent with its known profile in metastatic CRPC.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.